TAKEDA PHARMA A/S: Financial statements 2023
CVR: 16406899
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
TAKEDA PHARMA A/S (CVR 16406899) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,061,206,000 and a net result of DKK 13,573,000 compared with DKK 31,795,000 the year before. That is an increase of 16.6% compared with the year before. The profit margin was 1.3%. Equity in the 2023 report amounted to DKK 94,892,000. The solvency ratio was 19.5%. The company had 70 employees in the financial year.
- Revenue
- DKK 1,061,206,000
- Gross Profit
- DKK 120,582,000
- Profit/Loss
- DKK 13,573,000
- Equity
- DKK 94,892,000
- Total Assets
- DKK 485,750,000
- Employees
- 70
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 1.1B | 120.6M | 13.6M | 94.9M | 70 |
| 2022 | 910.1M | 154M | 31.8M | 81.2M | 180 |
| 2021 | 1.9B | 1.1B | 667.7M | 1B | 174 |
| 2020 | 1.6B | 3.2B | 2.7B | 2.7B | 179 |
| 2019 | 1.6B | 562.3M | 84.7B | 1.3B | 177 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of March 31, 2023, Vatroslav Mateljic has joined the board of directors of TAKEDA PHARMA A/S.
As of March 31, 2023, Duarte Joao Lourinho Marchand has left the board of directors of TAKEDA PHARMA A/S.
About TAKEDA PHARMA A/S
TAKEDA PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1984. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NYCOMED DANMARK ApS and NYCOMED DANMARK A/S. The management consists of Enor Cerimagic. The board consists of Koki Sato (chair), Enor Cerimagic, Jesper Lindahl and Malene Kelstrup. The company is owned by Takeda Pharmaceuticals International AG. The company has 79 employees (2026). In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. Equity in the 2026 report amounted to DKK 456,501,000.